Report Summary
Stem cell therapy-the emerging therapy area that is drawing the attention of the pharmaceutical players worldwide-refers to the therapy wherein a damaged tissue that cannot heal itself is repaired by the use of stem cell. The market for stem cells is constantly evolving, with researches going on to exploit the true potential of the market worldwide. Stem cell has emerged as an important market in the US which continues to witness massive investments in this research arena. The US has seen some major achievements in the treatment of the diseases using stem cell technologies. The market has shown remarkable growth since 2005, when the first stem cell product entered into the market. The stem cell therapy market reported a CAGR growth of around 18% in a short period spanning from 2005 to 2008, says our new research report, "US Stem Cell Market Analysis".
The revenue is expected to increase manifold with new stem cell products likely to enter into the market in 2009 and onwards. As the market currently remains in its nascent stage, our team of experts has done thorough analysis of the prevailing trends and developments of the stem cell market in the US. We have studied the US stem cells product market in terms of adult stem cells and embryonic stem cells. This report provides extensive research on the current status and future outlook of these two segments.
We have found that the US embryonic stem cell product market suffered a setback due to the eight year old ban on federal funding of the embryonic stem cells imposed under the Bush Administration. The recent reversal of the ban by Obama on federal funding for the research has opened up new avenues for the market. On technological front, this report studies the stem cells market as therapeutic banking and cellular therapeutics.
The prevalence of the major diseases among people with no permanent cure available and the dependency on medicines for sustainability and well-being provides the ready market for the stem cell companies to tap.
"US Stem Cell Market Analysis" provides extensive research and thorough analysis of the current industry trends driving the growth of stem cell market in the US. This report highlights the emerging segments in the market alongwith their market potential to serve the country's population. The report will help the clients to understand the market dynamics and get an insight of the current and the future outlook of stem cells market in the US
Table of Contents
1. Analyst View
2. US Stem Cell Market Overview
2.1 Understanding Stem Cell
2.2 Stem Cell Market
3. Stem Cell Therapy Market Structure
3.1 By Product
3.1.1 Adult Stem Cell
3.1.2 Embryonic Stem Cell
3.2 By Technology
3.2.1 Therapeutic Banking
3.2.2 Cellular Therapeutics
4. Emerging Areas for Therapeutic Applications
4.1 Spinal Cord Injury
4.2 Biologicals and Associated Hardware
4.3 Myocardial Infarction
4.4 Limb Ischemia
5. Industry Trends
5.1 Potential Patient Population
5.2 Costly Treatments
5.3 Rising Healthcare Spending
5.4 Government Initiatives
5.5 Unmet Medical Needs
5.6 Stem Cell-An Emerging Therapy
5.7 Regulatory Constraints and Political Interference
5.8 Need for Universal Allogenic Treatments
6. Key Players
6.1 Geron Corporation
6.2 StemCells Inc.
6.3 Advanced Cell Technology Inc
6.4 Neuralstem Inc.
6.5 Aastrom Biosciences Inc
6.6 Thermogenesis Corp
List of Figures:
Figure 2-1: Stem Cell Therapy Development Process
Figure 2-2: Stem Cell Market by Region (%), 2005
Figure 2-3: Forecast for Stem Cell Market by Region (%), 2010
Figure 2-4: Share in Global Cord Blood Bank Market (2007)
Figure 2-5: Cord Blood Bank by Region (%), 2005
Figure 3-1: Stem Cell Therapy Market (Million US$), 2005-2008
Figure 3-2: Forecast for Stem Cell Therapy Market (Million US$), 2009-2012
Figure 3-3: Stem Cell Product Sales (Million US$), 2006-2008
Figure 3-4: Forecast for Stem Cell Product Sales (Million US$), 2009-2012
Figure 3-5: Adult Stem Cell Product Market (Million US$), 2007 & 2009
Figure 3-6: Cord Blood Bank Market (Million US$), 2007 & 2010
Figure 3-7: Cord Blood Inventory in Public and Private Banks (Million), H1 2008
Figure 3-8: Cord Blood Inventory in Public Banks by Place (Million), H1 2008
Figure 3-9: Therapeutic Banking Market (Million US$), 2005-2008
Figure 3-10: Forecast for Therapeutic Banking Market (Million US$), 2009-2012
Figure 3-11: Cellular Therapeutics Market (Million US$), 2005-2008
Figure 3-12: Forecast for Cellular Therapeutic Market (Million US$), 2009-2012
Figure 4-1: Patients Suffering from Spinal Cord Injury (Million), 2006, 2008 & 2009
Figure 4-2: Patients Suffering from Myocardial Infarction (Million), 2006 & 2008
Figure 5-1: Per Head Healthcare Spending (US$), 2005-2008
Figure 5-2: Leading Causes of Death (Numbers)
List of Tables:
Table 4-1: Stem Cell Therapy Market Potential in Spinal Cord Injury (2009)
Table 5-1: Potential Patient Population for Stem Cell Therapy (Million), 2005
Table 5-2: Annual Direct Expenditures for Selected Diseases (Billion US$), 2005
Table 5-3: Stem Cell Therapy Cost Comparison to Leading Treatment (Million US$)
